Immutep Reports P-I Trial (INSIGHT-003) Results of Triple Combination Therapy as 1L Treatment of Non-Small Cell Lung Cancer
- The P-I trial (INSIGHT-003) evaluating eftilagimod alpha (soluble LAG-3 protein & MHC Class II agonist) + SoC anti-PD-1 therapy & doublet CT. The trial was conducted by the Frankfurt Institute of Clinical Cancer Research IKF
- The results showed that the triple combination therapy was well-tolerated & showed promising initial efficacy signals, ORR (67%), DCR (91%), 81% had a PD-L1 TPS of <50% who are less responsive to anti-PD-1 based therapy vs PD-L1 high expressing patients & 65% response rate in patients with PD-L1 TPS <50%
- Additional results from the P-I trial are expected to be presented at a major medical conference in H2’23. The therapy received FTD in 1L HNSCC & NSCLC from the US FDA
Ref: Globenewswire | Image: Immutep
Related News:- Immutep Enters into a Clinical Trial Collaboration with Merck KGaA and Pfizer to Evaluate Eftilagimod Alpha (Efti) for Urothelial Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at [email protected]
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].